Drug Profile
Research programme: small molecule compounds - Merck/Nuevolution
Latest Information Update: 31 Jul 2019
Price :
$50
*
At a glance
- Originator Nuevolution
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 30 Jul 2019 Nuevolution has been acquired by Amgen
- 28 Jul 2018 No recent reports of development identified for preclinical development in Undefined in Denmark
- 20 Feb 2014 Preclinical trials in Undefined indication in Denmark (unspecified route)